Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas

Hepato-Gastroenterology

Volumn 46, Issue 28, 1999, Pages 2299-2308

  Fujii, Tsuneshi ^a   Obara, Takeshi ^a   Tanno, Satoshi ^a   Ura, Hitoshi ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Colorectal carcinomas; Plasminogen activator; Prognosis

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MESSENGER RNA SYNTHESIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA-DIRECTED DNA POLYMERASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032883153     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ellis V, Pyke C, Eriksen J, Solberg H, Deno K: The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992; 667:13-31.
2. Janicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991: 17:303-312.
3. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen G, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW, Verspaget HW: Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 1996; 77:1035-1043.
4. Saksela O: Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823:35-65.
5. Jankun J, Merrick HW, Goldblatt PJ: Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Biochemistry 1993; 53:135-144.
6. Kirchheimer JC, Huber K, Wagner O, Binder BR: Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. British Journal of Haematology 1987; 66:85-89.
7. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of colon in human. Am J Pathol 1991; 138:111-117.
8. Sier CFM, Fellbaum C, Verspaget HW, Schmitt M, Griffioen G, Graeff H, Hofler H, Lamers CBHW: Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 1991; 19:231-237.
9. Sato T, Nishimura G, Yonemura Y, Nojima N, Ninomiya I, Fujimura T, Sugiyama K, Miwa K, Miyazaki I, Nonomura A, Yamaguchi Y: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995; 52:347-352.
10. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344:583-584.
11. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Research 1993; 53:2513-2521.
12. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW: Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34:80-85.
13. Pedersen H, Brunner N, Francis D, Oesterlind K, Roenne E, Hoi Hansen H, Dano K, Grondahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54:4671-4675.
14. Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y, Sasaki T: Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 1996; 427:487-496.
15. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 1985; 13:2759-2771.
16. Bosma PJ, Berg EA, Kooistra T, Siemieniak DR, Slightom JL: Human plasminogen activator inhibitor-1 gene. J Biol Chem 1988; 263:9129-9141.
17. Nakajima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci 1985; 82:6133-6137.
18. Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ: The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. J Cell Biol 1990; 110:155-163.
19. Corasanti JG, Celik C, Camiolo SM, Mittelman A, Evers JL, Barbasch A, Hobika GH, Markus G: Plasminogen activator content of human colon tumors and normal mucosae: Separation of enzymes and partial purification. J Natl Cancer Inst 1980; 65:345-351.
20. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW: Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47:4654-4657.
21. de Bruin PAF, Verspaget HW, Griffioen G, Nap M, Verheijen JH, Lamers CBHW: Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1987; 1:57-62.
22. Tissot JD, Hauert J, Bachmann F: Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 1984; 34:295-302.
23. Gelister JSK, Mahmoud M, Lewin MR, Gaffney PJ, Boulos PB: Plasminogen activators in human colorectal neoplasia. Br J Med 1986; 293:728-731.
24. Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A: Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 1983; 43:5517-5525.
25. Naitoh H, Eguchi Y, Ueyama H, Kodama M, Hattori T: Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1,2 and plasminogen in colon cancer. Jpn J Cancer Res 1995; 86:48-56.
26. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, Hioki K, Yamamoto M: Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 1991; 48:20-27.
27. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O: Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer 1991; 48:481-484.
28. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA: Type 1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992; 50:208-214.
29. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen G, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW, Verspaget HW: Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' B and C colorectal cancer. Br J Cancer 1997; 75:1793-1801.
30. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder J, Fink U, Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994: 54:2900-2907.
31. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Boer A, Welvaart K, Velde CJH, Krieken JHJM, Verheijen JH, Lamers CBHW, Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54:4065-4071.